TPIA:OTC-Mycotopia Therapies Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.014

Change

0.00 (0.00)%

Market Cap

USD 0.10M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Mycotopia Therapies, Inc. focuses on psychedelics for the treatment of mental health issues. It provides psychedelic therapies for the treatment of post-traumatic stress disorder, palliative care, depression, and anxiety. The company is based in Miami, Florida. Mycotopia Therapies, Inc. is a subsidiary of EHAVE, Inc.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 36.93B
UCBJY UCB SA ADR

N/A

USD 36.22B
UCBJF UCB SA

N/A

USD 36.22B
GNMSF Genmab A/S

N/A

USD 13.91B
WXIBF WuXi Biologics

N/A

USD 10.26B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 9.12B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.24B
ZLDPF Zealand Pharma A/S

N/A

USD 8.01B
IVBIY IVBIY

N/A

USD 7.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.73B

ETFs Containing TPIA

IDX VanEck Indonesia Index ET.. 4.73 % 0.57 %

N/A

USD 0.03B
H4ZT:XETRA HSBC MSCI Indonesia UCITS.. 2.85 % 0.00 %

N/A

USD 0.10B
HIDR:SW HSBC MSCI Indonesia UCITS.. 2.85 % 0.00 %

N/A

USD 0.12B
EIDO iShares MSCI Indonesia ET.. 0.00 % 0.59 %

N/A

USD 0.27B
OBOR KraneShares MSCI One Belt.. 0.00 % 0.79 %

N/A

USD 3.37M
HIDD:LSE HSBC MSCI Indonesia UCITS.. 0.00 % 0.00 %

N/A

N/A
HIDR:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

N/A
H4ZT:F HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

N/A
WWJD Inspire International ESG.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.50% 59% D- 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.50% 59% D- 44% F
Trailing 12 Months  
Capital Gain -37.78% 44% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.78% 44% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -41.52% 10% F 3% F
Dividend Return -41.52% 10% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.99% 68% D+ 51% F
Risk Adjusted Return -81.42% 15% F 7% C-
Market Capitalization 0.10M 16% F 8% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector